Documents

Clinical investigation of the efficacy of the use of a new plant-based product in children with acute rhinosinusitis

CHERNISHEVA L.
Doctor of Medicine, Professor,
Department of Infectious Diseases
and Clinical Immunology in Childhood, Kiev

SINIACHENKO V.
Doctor of Medicine,
Department of Paediatric Otorhinolaryngology, Kiev

Therapeutics and Clinical Risk Management.
Special Issue in Spanish. Supplement I 2006.
Therapeutics and clinical risk management 2006 - PDF


ABSTRACT

In spite of the treatments currently available, the incidence of rhinosinusitis continues to be high in childhood. On the other hand, the treatments currently available are associated with side effects. Recently, a product obtained from natural plant extracts has been introduced.
Its action consists of facilitating natural drainage of pathological mucus secretion from the nasal and paranasal sinuses after intranasal administration.

The purpose of the study was to assess the product’s use in children suffering from acute rhinosinusitis and study its effect on symptoms. In order to study these children extensively, the local immunity indexes in the upper respiratory tract mucous membranes were also analysed. 30 children with acute rhinosinusitis, aged between 7 and 14, were divided into two groups of 15 patients each. In the first group, the plant extract product was combined with standard therapy and the second group received only the standard therapy.

The study’s results show that, compared with basic therapy, the treatment that included administration of the plant extracts as part of the therapy showed a more positive evolution of the clinical symptom rates, together with improved local immune reactivity in the mucous membranes.

Consequently, use in children with acute rhinosinusitis is very effective and safe.


Use of a plant-based product in children with acute rhinosinusitis - Full article

Therapeutics and clinical risk management 2006 - Index

Use in the early postoperative care of patients with productive rhinosinusitis - Next abstract

Hartington Pharma owns Nasodren® for sinusitis treatment